Literature DB >> 31062422

Regulatory mechanisms mediated by peroxisome proliferator-activated receptor-β/δ in skin cancer.

Jeffrey M Peters1, Dae J Kim2, Moses T Bility3, Michael G Borland4, Bokai Zhu5, Frank J Gonzalez6.   

Abstract

Considerable progress has been made during the past 20 years towards elucidating the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in skin cancer. In 1999, the original notion that PPARβ/δ was involved with epithelial cell function was postulated based on a correlation between PPARβ/δ expression and the induction of messenger RNAs encoding proteins that mediate terminal differentiation in keratinocytes. Subsequent studies definitively revealed that PPARβ/δ could induce terminal differentiation and inhibit proliferation of keratinocytes. Molecular mechanisms have since been discovered to explain how this nuclear receptor can be targeted for preventing and treating skin cancer. This includes the regulation of terminal differentiation, mitotic signaling, endoplasmic reticulum stress, and cellular senescence. Interestingly, the effects of activating PPARβ/δ can preferentially target keratinocytes with genetic mutations associated with skin cancer. This review provides the history and current understanding of how PPARβ/δ can be targeted for both nonmelanoma skin cancer and melanoma and postulates how future approaches that modulate PPARβ/δ signaling may be developed for the prevention and treatment of these diseases.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  cell cycle; differentiation; peroxisome proliferator-activated receptor-β/δ; skin cancer

Mesh:

Substances:

Year:  2019        PMID: 31062422      PMCID: PMC6692234          DOI: 10.1002/mc.23033

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  76 in total

Review 1.  Natural product-inspired synthesis of thiazolidine and thiazolidinone compounds and their anticancer activities.

Authors:  Qiu Zhang; Hongyu Zhou; Shumei Zhai; Bing Yan
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

Review 2.  The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention.

Authors:  Jeffrey M Peters; Yatrik M Shah; Frank J Gonzalez
Journal:  Nat Rev Cancer       Date:  2012-02-09       Impact factor: 60.716

3.  Peroxisome proliferator-activated receptor β/δ cross talks with E2F and attenuates mitosis in HRAS-expressing cells.

Authors:  Bokai Zhu; Combiz Khozoie; Moses T Bility; Christina H Ferry; Nicholas Blazanin; Adam B Glick; Frank J Gonzalez; Jeffrey M Peters
Journal:  Mol Cell Biol       Date:  2012-04-02       Impact factor: 4.272

Review 4.  Physiological functions of peroxisome proliferator-activated receptor β.

Authors:  Jaap G Neels; Paul A Grimaldi
Journal:  Physiol Rev       Date:  2014-07       Impact factor: 37.312

5.  Ligand-activated PPARδ modulates the migration and invasion of melanoma cells by regulating Snail expression.

Authors:  Sun Ah Ham; Taesik Yoo; Jung Seok Hwang; Eun Sil Kang; Won Jin Lee; Kyung Shin Paek; Chankyu Park; Jin-Hoi Kim; Jeong Tae Do; Dae-Seog Lim; Han Geuk Seo
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

6.  Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice.

Authors:  L Michalik; B Desvergne; N S Tan; S Basu-Modak; P Escher; J Rieusset; J M Peters; G Kaya; F J Gonzalez; J Zakany; D Metzger; P Chambon; D Duboule; W Wahli
Journal:  J Cell Biol       Date:  2001-08-20       Impact factor: 10.539

7.  Ligand activation of peroxisome proliferator-activated receptor-beta/delta inhibits cell proliferation in human HaCaT keratinocytes.

Authors:  Michael G Borland; Jennifer E Foreman; Elizabeth E Girroir; Reza Zolfaghari; Arun K Sharma; Shantu Amin; Frank J Gonzalez; A Catharine Ross; Jeffrey M Peters
Journal:  Mol Pharmacol       Date:  2008-08-07       Impact factor: 4.054

8.  Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines.

Authors:  Elizabeth E Girroir; Holly E Hollingshead; Andrew N Billin; Timothy M Willson; Gavin P Robertson; Arun K Sharma; Shantu Amin; Frank J Gonzalez; Jeffrey M Peters
Journal:  Toxicology       Date:  2007-11-04       Impact factor: 4.571

9.  Identification and characterization of a selective peroxisome proliferator-activated receptor beta/delta (NR1C2) antagonist.

Authors:  Barry G Shearer; David J Steger; James M Way; Thomas B Stanley; David C Lobe; Didier A Grillot; Marie A Iannone; Mitchell A Lazar; Timothy M Willson; Andrew N Billin
Journal:  Mol Endocrinol       Date:  2007-11-01

10.  Ligand activation of peroxisome proliferator-activated receptor-beta/delta and inhibition of cyclooxygenase-2 enhances inhibition of skin tumorigenesis.

Authors:  Moses T Bility; Bokai Zhu; Boo H Kang; Frank J Gonzalez; Jeffrey M Peters
Journal:  Toxicol Sci       Date:  2009-09-11       Impact factor: 4.109

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.